Sanofi's Diabetes Portfolio in Focus at American Diabetes Association Sessions - Analyst Blog

A pen and a pair of glasses on top of a graph
Credit: Shutterstock photo

Sanofi 's ( SNY ) diabetes segment, accounting for more than 20% of the company's total revenues, is currently in focus at the ongoing scientific sessions of the American Diabetes Association (ADA).

At ADA, Sanofi presented data from an 8-week, randomized, open-label, three-arm parallel study on its type II diabetes drug, Lyxumia. The study compared Lyxumia with Novo Nordisk 's ( NVO ) Victoza (liraglutide) in combination with Lantus (insulin glargine), another diabetes drug at Sanofi, with or without metformin. Greater reduction in post-prandial glucose (PPG) from baseline was observed in the Lyxumia arm compared to the Victoza arm.

Although both Lyxumia and Victoza were effective in lowering blood glucose levels, there were fewer reports of gastrointestinal adverse events, a lower mean increase in the heart rate and smaller increases from baseline to week 8 in pancreatic enzyme in the Lyxumia arm.

Meanwhile, Sanofi also presented data on its lead diabetes product, Lantus, which recorded revenues of €1.4 billion in the first quarter. The company presented data from a real world outcome study on type II diabetes patients. In the study it was found that switching from Lantus to Novo Nordisk's Levemir (insulin detemir) resulted in higher average blood sugar levels (A1C) and lower A1C reduction over a one-year period compared to maintaining patients on Lantus. In contrast, switching patients from Levemir to Lantus resulted in significantly lower A1C compared to maintaining patients on Levemir.

Sanofi is developing a new formulation of insulin glargine, Toujeo, for diabetes. Sanofi released data from a pooled analysis of Toujeo. According to the data, significantly fewer low blood sugar events (hypoglycemia) at any time of the day, including night-time events, were observed in patients receiving Toujeo as compared to Lantus. Toujeo is currently under regulatory review in Europe.

The company's diabetes segment has been performing well since the last few quarters. We expect investor focus to remain on the segment in the future.

Sanofi carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Gilead Sciences ( GILD ) and Allergan ( AGN ). Both Gilead and Allergan are Zacks Rank #1 (Strong Buy) stocks.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More